Ron Shalom Rosen, MD
Nuclear Medicine · Cupertino
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 19
- 4 carriers
- Offices
- 3
Offices
3 locations · Silicon Valley Diagnostic Imaging Inc · Inview Imaging Diagnostics Inc A Professional Medical Corporation
Looking this up.
Hospitals listed: Desert Regional Medical Center · El Camino Health. That is not proof they admit you there this week.
Plans that list them
19 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Rosen’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
19 of 19 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A96556 · Current
Licensed to practise in California · since 2006 · expires 2028-04-30 · Tel Aviv University, Sackler School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Desert Regional Medical CenterPalm Springs, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Tenet Healthcare, which runs 77 hospitals in 12 statesPatients rate it 2 of 5 · 62% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.286, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.398, Oct 2024 – Sep 2025
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Desert Regional Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 7 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.286 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.398 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.87) · 838 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.77 (0.39 to 1.15) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 203.66 (157.92 to 249.4) · 87 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 10.6 · 61 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.9 · 125 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.9 · 194 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.7 · 320 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 13.7 · 366 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.2 · 3,299 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.01 to 0.43) · 4,856 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.43) · 4,661 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.16 (0.09 to 4.24) · 1,071 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.66 (0 to 3.39) · 52 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.35 (0.82 to 3.89) · 1,085 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.77 (0 to 18.61) · 47 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.17 (0.86 to 9.49) · 41 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.97 (0.49 to 3.45) · 144 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.79) · 4,380 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 41 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.138 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.022 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14 · 280 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.5 · 407 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 36.9 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 35.9 · 220 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 31.6 · 324 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 530 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (3 to 6.4) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.7 (7.8 to 14.4) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.5 · 44 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.7 · 44 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.3 · 138 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 91 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,035 patients answered, 14% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 70% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 68% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 40% |
| "YES", patients would definitely recommend the hospital | 62% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$1,407,887
Medicare paid this office $1,407,887 for 802 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Nuclear medicine study from skull base to mid-thigh with ct scan | 289 | $485,688 | $1,577 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 49 | $221,109 | $511 |
| Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries | 49 | $146,939 | $2,939 |
| Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie | 28 | $114,550 | $807 |
| Nuclear medicine study whole body with ct scan | 73 | $110,216 | $1,489 |
See all 11 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 289 | $485,688 | $1,577 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 49 | $221,109 | $511 |
| Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries | 49 | $146,939 | $2,939 |
| Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie | 28 | $114,550 | $807 |
| Nuclear medicine study whole body with ct scan | 73 | $110,216 | $1,489 |
| Nuclear medicine study limited area with ct scan | 52 | $92,111 | $1,771 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 239 | $78,367 | $306 |
| Flotufolastat f 18, diagnostic, 1 millicurie | 17 | $70,881 | $549 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 337 | $37,959 | $100 |
| Nuclear medicine study whole body with ct scan | 44 | $4,418 | $98 |
| Imaging of retina for disease detection, with automated review and report at point of care | 49 | $2,291 | $46 |
Who their Medicare patients are
802 Original Medicare patients in 2024. Average age 76 · Under 65 5% · 85 and older 17% · Women 42% · Also on Medicaid 21% · Health risk score 2.17. Above the middle of the specialty; the typical nuclear medicine clinician is at 1.94.
Conditions among them: High blood pressure 75% · Cancer 58% · Diabetes 33% · Coronary heart disease 32% · Chronic kidney disease 27% · Atrial fibrillation 21% · Depression 19% · Heart failure 18% · COPD 18% · Dementia 14% · Stroke 11%.
The office billed $4,395,498, Medicare allowed $1,769,204 and paid $1,407,887; for 2,646 services of 25 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 802 | 2,646 | 76 | 2.17 | $4,395,498 | $1,407,887 |
| 2023 | 852 | 5,878 | 75 | 2.19 | $6,281,084 | $2,464,694 |
| 2022 | 866 | 9,546 | 74 | 2.05 | $6,460,170 | $2,633,092 |
| 2021 | 701 | 3,999 | 73 | 2.20 | $4,890,636 | $1,711,159 |
| 2020 | 319 | 3,114 | 73 | 2.31 | $1,974,544 | $673,276 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 610 | $957,257 | $1,482 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 212 | $918,032 | $467 |
| Nuclear medicine study whole body with ct scan | 186 | $277,185 | $1,451 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 504 | $132,928 | $247 |
| Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie | 17 | $71,411 | $840 |
| Gallium ga-68, dotatate, diagnostic, 0.1 millicurie | 25 | $56,944 | $42 |
| Ct scan of abdomen and pelvis with contrast | 15 | $4,562 | $304 |
| Nuclear medicine study of bone and/or joint whole body | 12 | $3,449 | $265 |
| Ct scan of chest with contrast | 21 | $2,569 | $122 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 12 | $151 | $12 |
2022: 12 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 625 | $1,050,741 | $1,566 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 219 | $919,809 | $439 |
| Nuclear medicine study whole body with ct scan | 165 | $275,765 | $1,567 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 524 | $147,202 | $252 |
| Gallium ga-68, dotatate, diagnostic, 0.1 millicurie | 47 | $115,148 | $44 |
| Fluciclovine f-18, diagnostic, 1 millicurie | 22 | $87,133 | $396 |
| Ct scan of abdomen and pelvis with contrast | 29 | $9,696 | $323 |
| Nuclear medicine study of bone and/or joint whole body | 27 | $8,590 | $307 |
| Ct scan of chest with contrast | 27 | $3,243 | $116 |
| Ct scan of chest without contrast | 23 | $2,922 | $127 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 32 | $396 | $12 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 29 | $283 | $0 |
2021: 10 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 495 | $824,231 | $1,501 |
| Nuclear medicine study whole body with ct scan | 174 | $275,477 | $1,522 |
| Fluciclovine f-18, diagnostic, 1 millicurie | 66 | $222,072 | $382 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 517 | $137,266 | $240 |
| Positron emission tomography radiopharmaceutical, diagnostic, for tumor identification, not otherwise classified | 32 | $115,610 | $3,613 |
| Gallium ga-68, dotatate, diagnostic, 0.1 millicurie | 34 | $95,193 | $52 |
| Ct scan of abdomen and pelvis with contrast | 24 | $8,518 | $315 |
| Nuclear medicine study of bone and/or joint whole body | 16 | $5,622 | $331 |
| Ct scan of chest with contrast | 32 | $4,317 | $120 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 16 | $202 | $12 |
2020: 9 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 218 | $323,926 | $1,446 |
| Nuclear medicine study whole body with ct scan | 92 | $142,284 | $1,482 |
| Fluciclovine f-18, diagnostic, 1 millicurie | 23 | $75,472 | $328 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 265 | $63,119 | $231 |
| Gallium ga-68, dotatate, diagnostic, 0.1 millicurie | 21 | $58,796 | $52 |
| Ct scan of abdomen and pelvis with contrast | 13 | $4,052 | $312 |
| Ct scan of chest with contrast | 18 | $2,476 | $138 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 12 | $97 | $0 |
| Blood creatinine level | 17 | $87 | $5 |
Medicaid work
$8,378 in 2024
Medicaid paid $8,378 for 40 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 27 | $8,378 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 13 | $0 |
| 2024 | 40 | 2 | 15 | $8,378 |
| 2023 | 121 | 2 | 14 | $56,517 |
| 2022 | 148 | 2 | 18 | $65,845 |
| 2021 | 165 | 2 | 19 | $44,170 |
| 2020 | 245 | 2 | 21 | $107,971 |
See the largest Medicaid services in earlier years
2023
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 65 | $51,621 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 56 | $4,896 |
2022
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 53 | $57,332 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 95 | $8,512 |
2021
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 75 | $37,772 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 90 | $6,397 |
2020
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 113 | $96,440 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 132 | $11,530 |
Money from drug and device companies
$181 in 2025
| 2025 | 3 | 4 | None | $181 |
| 2024 | 2 | 2 | None | $59 |
| 2022 | 1 | 1 | None | $22 |
| 2019 | 1 | 1 | None | $18 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Telix Pharmaceuticals | Illuccix | $133 | 2 payments
|
| Kite Pharma | Yescarta | $24 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $23 | 1 payment
|
See all 4 published payments
| Kite Pharma | Meals · 2025-12-03 | Yescarta | $24 |
| Progenics Pharmaceuticals | Meals · 2025-11-19 | Pylarify | $23 |
| Telix Pharmaceuticals | Meals · 2025-06-18 | Illuccix | $70 |
| Telix Pharmaceuticals | Meals · 2025-06-18 | Illuccix | $63 |
See earlier years (2024, 2022, 2019)
2024: $59
| Novartis Pharmaceuticals | Pluvicto | $31 | 1 payment
|
| Lilly USA | Amyvid | $28 | 1 payment
|
2022: $22
| Blue Earth Diagnostics | Axumin | $22 | 1 payment
|
2019: $18
| AstraZeneca Pharmaceuticals LP | Tagrisso | $18 | 1 payment
|
Professional record
- NPI
- 1750331468
- Licence
- CA A96556, DC MD34026, NY 302292California A96556: Current · expires 2028-04-30
- Group
- Silicon Valley Diagnostic Imaging Inc · Inview Imaging Diagnostics Inc A Professional Medical Corporation
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207U00000X (207U00000X); Federal specialty code 174400000X (174400000X)
- Mailing address
- 1 Gustave L Levy Pl, New York, NY, 10029
- NPI first listed
- 2006-05-11
- NPI last updated
- 2021-03-25
- NPI record certified
- 2021-03-25
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2211 Moorpark Ave Ste 220, San Jose, CA, 95128